B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success

The medical community is celebrating a historic milestone as a British Columbia man, Patrick Magri, has been declared functionally cured of Hereditary Angioedema (HAE) using a revolutionary in-vivo gene-editing technology. This development represents the first time a patient has been successfully treated for this rare, life-threatening condition through a single dose of CRISPR-based therapy, potentially ending a lifetime of debilitating swelling attacks and the need for constant prophylactic medication.

Hereditary Angioedema is a genetic disorder characterized by severe, unpredictable swelling in various parts of the body, including the hands, feet, face, and airway. For patients like Magri, the condition was not merely an inconvenience but a constant threat to life. Traditional treatments required regular injections or infusions to manage symptoms, but they could not address the underlying genetic cause. The therapy administered, known as NTLA-2002 and developed by Intellia Therapeutics, utilizes CRISPR/Cas9 technology to travel directly to the liver and knock out the KLKB1 gene. By disabling this gene, the body significantly reduces the production of kallikrein, a protein that triggers the overproduction of bradykinin, the peptide responsible for the characteristic swelling of HAE.

“

While a single dose may cost millions, proponents argue it is more cost-effective than decades of prophylactic treatment, which can exceed $500,000 per patient annually.

This case is particularly significant because it utilizes in-vivo editing—where the CRISPR components are delivered directly into the patient's bloodstream to find their target organ—rather than ex-vivo editing, where cells are removed, edited in a lab, and then re-infused. The success of NTLA-2002 in this B.C. patient follows Phase 1/2 clinical trial data showing a 95% mean reduction in monthly attack rates after a single administration. For many participants, the attacks stopped entirely, a result that has now been sustained long enough for clinicians to use the word 'cure'—a term rarely applied in the context of rare genetic diseases.